Literature DB >> 6425907

Effects of naloxone on methamphetamine and apomorphine stereotypy and on haloperidol catalepsy in rats.

J J Balsara, N V Nandal, N P Burte, J H Jadhav, A G Chandorkar.   

Abstract

Pretreatment with the opiate antagonist naloxone, at 1.25-5 mg/kg, increased the intensity of methamphetamine stereotypy, had no effect (over a range of 0.3125-5 mg/kg) on apomorphine stereotypy, and antagonized haloperidol catalepsy in rats at 1.25-5 mg/kg. It is suggested that naloxone, by blocking the opiate receptors located on the nigro-striatal and mesolimbic dopamine (DA) nerve terminals, releases the DA systems from endogenous inhibition, presumably caused by endogenous opiate systems, and thereby potentiates methamphetamine stereotypy and antagonizes haloperidol catalepsy. However, the possibility that naloxone might have affected methamphetamine stereotypy and haloperidol catalepsy by modulating the activity of the central noradrenergic and GABAergic systems, which are reported to influence dopaminergically mediated behaviours, also needs to be considered.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6425907     DOI: 10.1007/bf00427781

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  Binding of opiates and endogenous opioid peptides to neuroleptic receptor sites in the corpus striatum.

Authors:  A Członkowski; V Höllt; A Herz
Journal:  Life Sci       Date:  1978-03       Impact factor: 5.037

2.  Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain.

Authors:  S J Peroutka; D C U'Prichard; D A Greenberg; S H Snyder
Journal:  Neuropharmacology       Date:  1977-09       Impact factor: 5.250

3.  GABA involvement in neuroleptic-induced catalepsy.

Authors:  P Worms; M T Willigens; K G Lloyd
Journal:  J Pharm Pharmacol       Date:  1978-11       Impact factor: 3.765

4.  Differential cataleptogenic and antistereotypic effects of caerulein and haloperidol.

Authors:  G Zetler
Journal:  Neuropharmacology       Date:  1981-07       Impact factor: 5.250

5.  Synthetic enkephalin analogue in treatment of schizophrenia.

Authors:  A Jørgensen; R Fog; B Veilis
Journal:  Lancet       Date:  1979-04-28       Impact factor: 79.321

Review 6.  Opiate receptors and opioid peptides.

Authors:  S H Snyder; S R Childers
Journal:  Annu Rev Neurosci       Date:  1979       Impact factor: 12.449

7.  The pharmacological and anatomical substrates of the amphetamine response in the rat.

Authors:  I Creese; S D Iversen
Journal:  Brain Res       Date:  1975-01-17       Impact factor: 3.252

8.  Noradrenergic influences on catalepsy.

Authors:  S T Mason; D C Roberts; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1978-12-15       Impact factor: 4.530

9.  Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies.

Authors:  R Dingledine; L L Iversen; E Breuker
Journal:  Eur J Pharmacol       Date:  1978-01-01       Impact factor: 4.432

10.  Enkephalin, morphine, and naloxone in tardive dyskinesia.

Authors:  N Bjørndal; D E Casey; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  3 in total

1.  Influence of naloxone upon motor activity induced by psychomotor stimulant drugs.

Authors:  D N Jones; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

2.  Interactions of morphine with apomorphine: behavioural and biochemical studies.

Authors:  H G Möller; K Kuschinsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-12       Impact factor: 3.000

3.  Naloxone Ameliorates Spatial Memory Deficits and Hyperthermia Induced by a Neurotoxic Methamphetamine Regimen in Male Rats.

Authors:  Solmaz Khalifeh; Mehdi Khodamoradi; Vahid Hajali; Hamed Ghazvini; Lelia Eliasy; Afshin Kheradmand; Vahid Farnia; Javad Akhtari; Kaveh Shahveisi; Hossein Ghalehnoei
Journal:  Galen Med J       Date:  2019-04-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.